Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Europe sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, FY2023
12
Period ended Dec 31, 2023
Change on a year earlier
-29.4%
17 in FY2022
History
8 years
Since FY2016
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 12 | -29.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 17 | -45.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 31 | +6.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 29 | -59.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 71 | -50.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 144 | -79.5% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 704 | -61.1% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1,810 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Europe sales ($M) ($M), annual FY2016–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_harvoni_eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.